Literature DB >> 15449141

HIV-1 Vpr enhances production of receptor of activated NF-kappaB ligand (RANKL) via potentiation of glucocorticoid receptor activity.

J M Fakruddin1, J Laurence.   

Abstract

The HIV-1 accessory protein Vpr potentiates glucocorticoid (GC)-induced inhibition of a variety of immunologically important cytokines. We report the first instance of synergy between Vpr and GC in induction of a T cell cytokine, one which may underlie a metabolic complication of HIV infection. Accelerated bone resorption is an important complication of HIV disease and its treatment. Receptor of activated NF-kappaB ligand (RANKL) is the final effector of osteoclast differentiation and bone resorption. It is induced by exogenous GC, a prominent cofactor in bone mineral loss, as well as by elevated levels of endogenous GC, found in many patients with HIV disease. We document Vpr-mediated upregulation of RANKL, the dependence of this effect on GC receptor integrity, its function through a classic GC receptor motif, and its independence from Vpr-mediated G(2) cell cycle arrest. These data suggest a positive regulatory role for Vpr in transcriptional control of a cytokine that may be critical to one metabolic complication of HIV.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15449141     DOI: 10.1007/s00705-004-0395-7

Source DB:  PubMed          Journal:  Arch Virol        ISSN: 0304-8608            Impact factor:   2.574


  36 in total

Review 1.  Care of the human immunodeficiency virus-infected menopausal woman.

Authors:  Helen Elizabeth Cejtin
Journal:  Am J Obstet Gynecol       Date:  2011-12-30       Impact factor: 8.661

Review 2.  Incident fractures in HIV-infected individuals: a systematic review and meta-analysis.

Authors:  Stephanie Shiau; Emily C Broun; Stephen M Arpadi; Michael T Yin
Journal:  AIDS       Date:  2013-07-31       Impact factor: 4.177

Review 3.  The role of bone cells in immune regulation during the course of infection.

Authors:  Asuka Terashima; Hiroshi Takayanagi
Journal:  Semin Immunopathol       Date:  2019-09-24       Impact factor: 9.623

4.  Vitamin D, osteoprotegerin/receptor activator of nuclear factor-kappaB ligand (OPG/RANKL) and inflammation with alendronate treatment in HIV-infected patients with reduced bone mineral density.

Authors:  J Natsag; M A Kendall; D E Sellmeyer; G A McComsey; T T Brown
Journal:  HIV Med       Date:  2015-07-16       Impact factor: 3.180

5.  Bone Quality Measured Using Calcaneal Quantitative Ultrasonography Is Reduced Among Children with HIV in Johannesburg, South Africa.

Authors:  Stephen M Arpadi; Cara B Thurman; Faeezah Patel; Jonathan J Kaufman; Renate Strehlau; Megan Burke; Stephanie Shiau; Ashraf Coovadia; Michael T Yin
Journal:  J Pediatr       Date:  2019-08-29       Impact factor: 4.406

Review 6.  Bone changes and fracture risk in individuals infected with HIV.

Authors:  Amy H Warriner; Michael J Mugavero
Journal:  Curr Rheumatol Rep       Date:  2010-06       Impact factor: 4.592

7.  Bone mineral density and fractures in antiretroviral-naive persons randomized to receive abacavir-lamivudine or tenofovir disoproxil fumarate-emtricitabine along with efavirenz or atazanavir-ritonavir: Aids Clinical Trials Group A5224s, a substudy of ACTG A5202.

Authors:  Grace A McComsey; Douglas Kitch; Eric S Daar; Camlin Tierney; Nasreen C Jahed; Pablo Tebas; Laurie Myers; Kathleen Melbourne; Belinda Ha; Paul E Sax
Journal:  J Infect Dis       Date:  2011-06-15       Impact factor: 5.226

8.  Bone effects of rosiglitazone in HIV-infected patients with lipoatrophy.

Authors:  Allison C Ross; Corrilynn O Hileman; Todd T Brown; Neal Fedarko; Norma Storer; Danielle Labbato; Grace A McComsey
Journal:  HIV Clin Trials       Date:  2012 Jul-Aug

Review 9.  Ageing and inflammation in patients with HIV infection.

Authors:  M Nasi; S De Biasi; L Gibellini; E Bianchini; S Pecorini; V Bacca; G Guaraldi; C Mussini; M Pinti; A Cossarizza
Journal:  Clin Exp Immunol       Date:  2016-08-09       Impact factor: 4.330

10.  Increased Fracture Incidence in Middle-Aged HIV-Infected and HIV-Uninfected Women: Updated Results From the Women's Interagency HIV Study.

Authors:  Anjali Sharma; Qiuhu Shi; Donald R Hoover; Kathryn Anastos; Phyllis C Tien; Mary A Young; Mardge H Cohen; Elizabeth T Golub; Deborah Gustafson; Michael T Yin
Journal:  J Acquir Immune Defic Syndr       Date:  2015-09-01       Impact factor: 3.731

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.